281 related articles for article (PubMed ID: 31278474)
1. A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis.
Jing Z; Rui Z; Binglan Z
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2313-2323. PubMed ID: 31278474
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
Zhang Q; Wang Q; Wang X; Li J; Shen L; Peng Z
Int J Colorectal Dis; 2020 Feb; 35(2):295-306. PubMed ID: 31848739
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
Chen J; Wang J; Lin H; Peng Y
Med Sci Monit; 2019 Dec; 25():9179-9191. PubMed ID: 31790382
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China.
Guan X; Li H; Xiong X; Peng C; Wang N; Ma X; Ma A
J Med Econ; 2021; 24(1):339-344. PubMed ID: 33571036
[TBL] [Abstract][Full Text] [Related]
5. A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis.
Abrahao ABK; Ko YJ; Berry S; Chan KKW
Clin Colorectal Cancer; 2018 Jun; 17(2):113-120. PubMed ID: 29174481
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review.
Wu Y; Fan Y; Dong D; Dong X; Hu Y; Shi Y; Jing J; Li E
Ther Adv Med Oncol; 2020; 12():1758835920940932. PubMed ID: 32728393
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World.
Zhang Q; Chen M; Wang Z; Qi C; Cao Y; Zhang J; Peng Z; Wang X; Lu M; Shen L; Li J
Clin Colorectal Cancer; 2022 Sep; 21(3):e152-e161. PubMed ID: 35216918
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review and Meta-Analysis of Multitargeted Tyrosine Kinase Inhibitors in Patients With Intractable Metastatic Colorectal Cancer.
Gao Z; Cao C; Bao Y; Fan Y; Chen G; Fu P
Technol Cancer Res Treat; 2020; 19():1533033820943241. PubMed ID: 32914703
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
Sonbol MB; Benkhadra R; Wang Z; Firwana B; Walden DJ; Mody K; Hubbard JM; Murad MH; Ahn DH; Bekaii-Saab T
Oncologist; 2019 Sep; 24(9):1174-1179. PubMed ID: 31164455
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer.
Xue WS; Men SY; Liu W; Liu RH
Medicine (Baltimore); 2018 Oct; 97(40):e12635. PubMed ID: 30290640
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
Xu RH; Li J; Bai Y; Xu J; Liu T; Shen L; Wang L; Pan H; Cao J; Zhang D; Fan S; Hua Y; Su W
J Hematol Oncol; 2017 Jan; 10(1):22. PubMed ID: 28103904
[TBL] [Abstract][Full Text] [Related]
12. Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib.
Cheng Y; Du FC; Fang FQ; Duan ZJ; Lei W; Shi KG
Neoplasma; 2020 Nov; 67(6):1384-1390. PubMed ID: 32657613
[TBL] [Abstract][Full Text] [Related]
13. Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis.
Casadei-Gardini A; Vagheggini A; Gelsomino F; Spallanzani A; Ulivi P; Orsi G; Rovesti G; Andrikou K; Tamburini E; Scartozzi M; Cascinu S
Clin Colorectal Cancer; 2020 Jun; 19(2):82-90.e9. PubMed ID: 32192883
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review.
Xie X; Zhang J; Hu H; Cai Y; Wu Z; Ling J; Li W; Deng Y
Adv Ther; 2020 Oct; 37(10):4233-4248. PubMed ID: 32770529
[TBL] [Abstract][Full Text] [Related]
15. Comparison of efficacy and safety for patients with beyond second line treated metastatic colorectal cancer: a network meta-analysis of randomized controlled trials.
Cao M; Zhou M; Zhang J
J Chemother; 2020 Jul; 32(4):163-170. PubMed ID: 32081104
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.
Røed Skårderud M; Polk A; Kjeldgaard Vistisen K; Larsen FO; Nielsen DL
Cancer Treat Rev; 2018 Jan; 62():61-73. PubMed ID: 29175677
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
[TBL] [Abstract][Full Text] [Related]
18. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.
Dasari A; Sobrero A; Yao J; Yoshino T; Schelman W; Yang Z; Chien C; Kania M; Tabernero J; Eng C
Future Oncol; 2021 Aug; 17(24):3151-3162. PubMed ID: 33993740
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study.
Dai Y; Sun L; Zhuang L; Zhang M; Zou Y; Yuan X; Qiu H
J Gastrointest Oncol; 2022 Apr; 13(2):722-731. PubMed ID: 35557597
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis.
Gao L; Tang L; Hu Z; Peng J; Li X; Liu B
Front Oncol; 2023; 13():1269203. PubMed ID: 37810981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
